306 related articles for article (PubMed ID: 25047667)
1. Milder course in Duchenne patients with nonsense mutations and no muscle dystrophin.
Zatz M; Pavanello RC; Lazar M; Yamamoto GL; Lourenço NC; Cerqueira A; Nogueira L; Vainzof M
Neuromuscul Disord; 2014 Nov; 24(11):986-9. PubMed ID: 25047667
[TBL] [Abstract][Full Text] [Related]
2. [Nonsense readthrough therapy for Duchenne muscular dystrophy].
Takeshima Y
Rinsho Shinkeigaku; 2014; 54(12):1074-6. PubMed ID: 25672712
[TBL] [Abstract][Full Text] [Related]
3. Analysis of dystrophin mRNA from skeletal muscle but not from lymphocytes led to identification of a novel nonsense mutation in a carrier of Duchenne muscular dystrophy.
Ito T; Takeshima Y; Yagi M; Kamei S; Wada H; Nakamura H; Matsuo M
J Neurol; 2003 May; 250(5):581-7. PubMed ID: 12736738
[TBL] [Abstract][Full Text] [Related]
4. Repression of phosphatidylinositol transfer protein α ameliorates the pathology of Duchenne muscular dystrophy.
Vieira NM; Spinazzola JM; Alexander MS; Moreira YB; Kawahara G; Gibbs DE; Mead LC; Verjovski-Almeida S; Zatz M; Kunkel LM
Proc Natl Acad Sci U S A; 2017 Jun; 114(23):6080-6085. PubMed ID: 28533404
[TBL] [Abstract][Full Text] [Related]
5. A novel approach to identify Duchenne muscular dystrophy patients for aminoglycoside antibiotics therapy.
Kimura S; Ito K; Miyagi T; Hiranuma T; Yoshioka K; Ozasa S; Matsukura M; Ikezawa M; Matsuo M; Takeshima Y; Miike T
Brain Dev; 2005 Sep; 27(6):400-5. PubMed ID: 16122626
[TBL] [Abstract][Full Text] [Related]
6. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations.
Wagner KR; Hamed S; Hadley DW; Gropman AL; Burstein AH; Escolar DM; Hoffman EP; Fischbeck KH
Ann Neurol; 2001 Jun; 49(6):706-11. PubMed ID: 11409421
[TBL] [Abstract][Full Text] [Related]
7. Milder course in Duchenne patients with nonsense mutations and no muscle dystrophin.
Castro-Gago M
Neuromuscul Disord; 2015 May; 25(5):443. PubMed ID: 25777491
[No Abstract] [Full Text] [Related]
8. Response to: Milder course in Duchenne patients with nonsense mutations and no muscle dystrophin.
Zatz M
Neuromuscul Disord; 2015 May; 25(5):444. PubMed ID: 25777492
[No Abstract] [Full Text] [Related]
9. The golden retriever model of Duchenne muscular dystrophy.
Kornegay JN
Skelet Muscle; 2017 May; 7(1):9. PubMed ID: 28526070
[TBL] [Abstract][Full Text] [Related]
10. Low-level dystrophin expression attenuating the dystrophinopathy phenotype.
Waldrop MA; Gumienny F; El Husayni S; Frank DE; Weiss RB; Flanigan KM
Neuromuscul Disord; 2018 Feb; 28(2):116-121. PubMed ID: 29305136
[TBL] [Abstract][Full Text] [Related]
11. Human adipose-derived mesenchymal stromal cells injected systemically into GRMD dogs without immunosuppression are able to reach the host muscle and express human dystrophin.
Vieira NM; Valadares M; Zucconi E; Secco M; Bueno CR; Brandalise V; Assoni A; Gomes J; Landini V; Andrade T; Caetano HV; Vainzof M; Zatz M
Cell Transplant; 2012; 21(7):1407-17. PubMed ID: 23168016
[TBL] [Abstract][Full Text] [Related]
12. Next Generation Sequencing approach to molecular diagnosis of Duchenne muscular dystrophy; identification of a novel mutation.
Ebrahimzadeh-Vesal R; Teymoori A; Azimi-Nezhad M; Hosseini FS
Gene; 2018 Feb; 644():1-3. PubMed ID: 29246534
[TBL] [Abstract][Full Text] [Related]
13. A normal life without muscle dystrophin.
Zatz M; Vieira NM; Zucconi E; Pelatti M; Gomes J; Vainzof M; Martins-Bach AB; Garcia Otaduy MC; Bento dos Santos G; Amaro E; Landini V; Andrade T
Neuromuscul Disord; 2015 May; 25(5):371-4. PubMed ID: 25770920
[TBL] [Abstract][Full Text] [Related]
14. Jagged 1 Rescues the Duchenne Muscular Dystrophy Phenotype.
Vieira NM; Elvers I; Alexander MS; Moreira YB; Eran A; Gomes JP; Marshall JL; Karlsson EK; Verjovski-Almeida S; Lindblad-Toh K; Kunkel LM; Zatz M
Cell; 2015 Nov; 163(5):1204-1213. PubMed ID: 26582133
[TBL] [Abstract][Full Text] [Related]
15. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
[TBL] [Abstract][Full Text] [Related]
16. Becker muscular dystrophy with widespread muscle hypertrophy and a non-sense mutation of exon 2.
Witting N; Duno M; Vissing J
Neuromuscul Disord; 2013 Jan; 23(1):25-8. PubMed ID: 22939275
[TBL] [Abstract][Full Text] [Related]
17. Protein- and mRNA-based phenotype-genotype correlations in DMD/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene.
Deburgrave N; Daoud F; Llense S; Barbot JC; Récan D; Peccate C; Burghes AH; Béroud C; Garcia L; Kaplan JC; Chelly J; Leturcq F
Hum Mutat; 2007 Feb; 28(2):183-95. PubMed ID: 17041906
[TBL] [Abstract][Full Text] [Related]
18. The position of nonsense mutations can predict the phenotype severity: A survey on the DMD gene.
Torella A; Zanobio M; Zeuli R; Del Vecchio Blanco F; Savarese M; Giugliano T; Garofalo A; Piluso G; Politano L; Nigro V
PLoS One; 2020; 15(8):e0237803. PubMed ID: 32813700
[TBL] [Abstract][Full Text] [Related]
19. Read-through approach for stop mutations in Duchenne muscular dystrophy. An update.
Politano L
Acta Myol; 2021 Mar; 40(1):43-50. PubMed ID: 33870095
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphism in muscle biopsies of Duchenne and Becker muscular dystrophy patients.
Anand A; Prabhakar S; Kaul D
Neurol India; 1999 Sep; 47(3):218-23. PubMed ID: 10514583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
